Lv55
1418 积分 2021-08-24 加入
High-affinity omalizumab variants with optimized disruptive potency prevent anaphylaxis in vivo
1天前
待确认
A trimer-disassembling anti-TL1A monoclonal antibody
1天前
求助中
Molecular mechanism of IgE-mediated FcεRI activation
8天前
已完结
Interleukin-33 in health and disease
24天前
已完结
The superiority of MabSelect VL, Cytiva's second-generation Protein L resin, over three other affinity resins in purifying a VHH-containing trispecific antibody
1个月前
已完结
Dual-epitope targeting of TSLP to simultaneously block TSLPR and IL-7Rα with a Biparatopic nanobody
1个月前
已完结
The complex patent situation regarding antibody Fc engineering
2个月前
已完结
Anti‐BDCA2 monoclonal antibody inhibits plasmacytoid dendritic cell activation through Fc‐dependent and Fc‐independent mechanisms
2个月前
已完结
Immunogenicity risk assessment and mitigation for engineered antibody and protein therapeutics
2个月前
已完结
Dual agonism and selective T-cell depletion activity of a PD-1-directed antibody for treating autoimmune diseases
3个月前
已完结
皖公网安备34019202002308
